An analysis of patients in the post first-line progressed study cohort revealed a significantly longer median overall survival (mOS) in patients who received two or more ALK TKIs compared to those who received only one ALK TKI throughout their cancer journey (55 months vs. 26 months, HR = 4.64, p < 0.0001). The gene discussed is ALK; the disease is cancer.